Getting your Trinity Audio player ready...
G.D. Searle & Co. said it entered into an agreement with Invitron Corp. to develop and market a new drug, known as tissue plasminogen activator, that offers potential for treatment and prevention of blood clots associated with heart attacks and other cardiovascular diseases.
